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Abstract
Background: Akt/PKB is a promising anticancer therapeutic target, since abnormally elevated Akt activity is directly
correlated to tumor development, progression, poor prognosis and resistance to cancer therapies. Currently, the unique
role of each Akt isoform and their relevance to human breast cancer are poorly understood.
Methodology/Principal Findings: We previously found that Akt1, 2 and 3 are localized at specific subcellular compartments
(the cytoplasm, mitochondria and nucleus, respectively), raising the possibility that each isoform may have unique functions
and employ different regulation mechanisms. By systematically studying Akt-ablated MDA-MB231 breast cancer cells with
isoform-specific siRNA, we here show that Akt2 is the most relevant isoform to cell proliferation and survival in our cancer
model. Prolonged ablation of Akt2 with siRNA resulted in cell-cycle arrest in G0/G1 by downregulating Cdk2 and cyclin D,
and upregulating p27. The analysis of the Akt downstream signaling pathways suggested that Akt2 specifically targets and
activates the p70S6K signaling pathway. We also found that Akt2 ablation initially resulted in an increase in the
mitochondrial volume concomitantly with the upregulation of PGC-1a, a regulator of mitochondrial biogenesis. Prolonged
ablation of Akt2, but not Akt1 or Akt3, eventually led to cell death by autophagy of the mitochondria (i.e., mitophagy).
Conclusions/Significance: Collectively, our data demonstrates that Akt2 augments cell proliferation by facilitating cell cycle
progression through the upregulation of the cell cycle engine, and protects a cell from pathological autophagy by
modulating mitochondrial homeostasis. Our data, thus, raises the possibility that Akt2 can be an effective anticancer target
for the control of (breast) cancer.
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Introduction
Akt serine/threonine kinase plays a crucial role in the regulation
of cell growth, proliferation, and survival. Constitutive activation
of the Akt pathway is associated with tumor development, poor
prognosis, and resistance to anticancer agents [1]. All three known
Akt isoforms (Akt1–3) show a high degree of sequence similarity,
and contain three functional domains: the N-terminal PH domain,
the catalytic domain in the middle, and the C-terminus [2,3].
Mainly due to technical difficulties, many published works do not
delineate Akt functions with each isoform. Therefore, some of the
known Akt functions may be applicable to one isoform but not
others, although the three Akt isoforms apparently share some
functional redundancy [4,5].
The availability of isoform-specific antibodies and siRNAs
allowed us to study the unique function of each Akt isoform. Using
these tools, we have recently found that Akt1–3 are localized
mainly to the cytoplasm, the mitochondria, and the nucleus,
respectively, in many cancer cell lines including cervical, breast,
and prostate cancer cells [6]. This specific subcellular localization
may ultimately underlie the regulation of isoform-specific
functions. Thus, it was hypothesized that a certain Akt isoform
may be more important for cell survival than the other isoforms
[7].
To gain a further understanding, we examined the specific role
played by each Akt isoform in the regulation of cell proliferation
and survival using the MDA-MB231 breast cancer model. The
isoforms (singularly or in combination) were ablated by selectively
targeting each isoform with isoform-specific siRNA. Cell survival,
cell proliferation, and cell cycle progression over a prolonged
period (0–120 h post-transfection) were examined. Downstream
substrates known to be regulated by Akt were also examined to
determine isoform-specific pathways. Our data shows that Akt2 is
most relevant to cell proliferation and survival among the three
Akt isoforms. Akt2 ablation resulted in the upregulation of p27
Kip1
(p27), and the downregulation of Cdk2 and cyclin D, leading to
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14614cell cycle arrest in G0/G1. Data obtained from the study of the
downstream Akt pathways suggests that Akt2 specifically regulates
the phosphorylation of p70S6K, a downstream target of mTOR.
We also found that the prolonged inactivation of Akt2 caused an
abnormal increase in mitochondrial volume and, eventually, led to
autophagy of the mitochondria (i.e., mitophagy). Collectively, our
data demonstrates that Akt2 is crucial for cell proliferation and
survival by facilitating cell cycle progression, augmenting p70S6K
activity, and modulating mitochondrial biogenesis.
Results
Akt2 ablation resulted in a substantial decrease in cell
proliferation
To study the unique role of each Akt isoform, siRNA
oligonucleotides were transfected into MDA-MB231 cells. This
cell line was chosen as a breast cancer model system, as we had
previously shown the subcellular localization of the Akt isoforms to
be consistent among MDA-MB231, MCF7, and MDA-MB468
breast cancer cell lines [8]. Given that MDA-MB231 cells are p53
negative and ER negative, the use of this cell line allowed us to
examine the unique role of the Akt isoforms in an aggressive model
of breast cancer. In addition, MDA-MB231 cells exhibit no known
alterations in the Akt pathway. As shown in Fig. 1A and Fig. S1A,
the Akt siRNA oligos used in our experiments effectively
downregulated the Akt proteins in an isoform-specific manner.
Isoform specificity of the oligonucleotides was confirmed by
Western blotting in these experiments and no cross-reactivity was
observed even when one Akt isoform-specific siRNA was used in
combination with other siRNA(s) (i.e., knockdown of Akt1 did not
knockdown Akt2 or Akt3) (Fig. 1A, lanes 1–7). The downregula-
tion of each Akt isoform was routinely achieved at the range of 40–
70% with both sets of isoform-specific siRNA oligos, which usually
coincided with the transfection efficiency, suggesting that these
isoform-specific siRNA oligos are highly effective.
To determine the role of each Akt isoform in cell survival, we
carried out a clonogenic assay. MDA-MB231 cells were transfected
with either set of two isoform-specific siRNA oligos, alone or in
combination with other isoform-specific oligo(s), followed by colony
formation analysis at 12–14 days post-transfection. The Akt2
knockdown caused the most significant decrease in the colony
forming ability among the three Akt isoforms (p,0.05) (Fig. 1B).
Colony-formation assays performed with the other set of siRNA
oligos showed a similar result (Fig. S1B).
To gain insight into the possible mechanism of how Akt2 may
promote cell survival, we examined cell proliferation in the Akt
knockdowns. Akt has previously been established as a critical
regulator of cell cycle progression (reviewed in [9]). However,
there are conflicting reports as to which Akt isoform is involved in
the regulation of cell cycle progression [10–15]. To determine if
the reduced colony formation observed in the Akt2-ablated cells
was due to a decrease in cell proliferation, MTT assays were
carried out with the cells transfected with isoform-specific siRNA
oligos at 48–120 h post-transfection. Data obtained from the
experiment demonstrated that knockdown of any Akt isoform
resulted in a decrease of cell proliferation by 120 h post-
transfection. However, the decrease in cell proliferation was most
pronounced with cells transfected with Akt2 siRNA (Fig. 1C).
Reduced cellular proliferation was also observed in the double
knockdown when Akt2 was one of the isoforms involved (i.e.,
Akt1/2 and/or Akt2/3); however, the double knockdown did not
show synergistic effects in cell proliferation. The relatively high
survival rate of the Akt1, 2 and 3 triple knockdown sample is
probably due to the low transfection efficiency often shown when
cells are transfected with all three isoform-specific siRNA oligos.
Alternatively, it is also possible that certain Akt isoforms may
(directly or indirectly) function antagonistically each other with
respect to cell proliferation and survival.
To further confirm the MTT data, DNA replication activities
were examined by analyzing incorporation of BrdU in cells
transfected with Akt2 siRNA. The results showed that the
incorporation of BrdU into DNA was dramatically decreased in
the cells transfected with Akt2 siRNA (p,0.001) (Fig. 1D). It
should be noted that cell proliferation was substantially reduced
both in siRNA-treated and scrambled siRNA-treated samples at
the 0 h timepoint. This is because cells were incubated in serum-
free medium for 24 h during the transfection procedure. (Note
that 0 h is defined as the end point of the 24-h transfection period).
When cells were in full serum for 24–48 h post-transfection, BrdU-
positive staining was observed only in the control samples,
confirming that Akt2-ablated cells were not proliferating
(p,0.001) (Fig. 1D). Data obtained with the Akt2 siRNA set #2
yielded a similar result (Fig. 1D).
Cdk2 is downregulated in the Akt2-ablated cells
We analyzed cell cycle progression by flow cytometry since cell
proliferation, survival, and DNA replication were downregulated
in the Akt2-ablated cells. Cells were transfected with Akt2 siRNA
in serum-free medium for 24 h. At the end of transfection (i.e., 0 h
timepoint), the medium was changed to complete medium
containing 10% FBS. The cell cycle profiles for the controls and
Akt2 siRNA-treated samples were similar at the 0 h timepoint,
which were consistent with those arrested at G0/G1 by serum
starvation (Fig. S2). Cells in the ‘‘Reagent’’ and ‘‘Kept-in-
incubator’’ controls progressed into the cell cycle by 24 h post-
transfection in the complete medium (Fig. S2). In contrast, cells
treated with Akt2 siRNA did not progress into the cell cycle at the
same timepoint (Fig. S2). Our data suggests that the decrease in
cell number observed in both MTT and clonogenic assays was not
due to an increase in cell death, at least by 48 h post-transfection,
since there was no substantial number of Akt2-ablated cells with
sub-G1 DNA content (Fig. S2).
To further investigate the mechanism of the cell cycle arrest in
the Akt2-ablated cells, we examined the levels of several proteins
involved in cell cycle control. We first chose Cdk2 as a primary
candidate, since published data suggested that Akt is involved in
the regulation of Cdk2 in an isoform-specific manner [16,17]. As
shown in Fig. S3A (upper and lower panels), the downregulation of
Cdk2 was obvious in the Akt2-ablated cells, but not in the Akt1-
and Akt3-ablated cells. We found that the level of Cdk2 was low
throughout the entire period when Akt2-ablated cells were
maintained in complete medium (i.e., 24–120 h post-transfection)
(Fig. 2A, upper and lower panels; Fig. S3B). The degree of Cdk2
downregulation was generally greater in the later timepoints after
Akt2 ablation. The downregulation of Cdk2 in the Akt2-ablated
cells was confirmed by indirect immunostaining with an anti-Cdk2
antibody (Fig. 2B).
We also examined the levels of cyclins A, D and E in the cells
treated with Akt2 isoform-specific siRNA. Cyclin D was
downregulated in Akt2-ablated cells, which is consistent with the
cell cycle arrest in G0/G1 in the Akt2-ablated cells (Fig. 2C; Fig.
S3C). Unexpectedly, the level of cyclin E was upregulated in
theAkt2-ablated cells (Fig. 2C; Fig. S3D). It was previously shown
that Cyclin E is degraded by the ubiquitin pathway through SCF-
Fbw-ubiquitin ligase and subsequent binding to Skp1 (reviewed in
[18]). The degradation of cyclin E is prevented when Cdk2-cyclin
E complexes are inhibited by p27, a Cdk inhibitor [19]. Thus,
Cdk2-p27 binding can inhibit the turnover of cyclin E. We found
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It should be noted that cyclin D was also downregulated in Akt1-
ablated cells, but not in Akt3-ablated cells (Fig. S4).
p27 was upregulated and localized in the nucleus of
Akt2-ablated cells
The finding that Akt2-ablated cells are arrested in G0/G1
prompted us to examine the level of p27, as its high level in the
nucleus is directly relevant to the cell cycle arrest at G0/G1.
Furthermore, p27 is also a known PI3K/Akt target, as the
inhibition of this signaling pathway with LY294002, wortmannin
or rapamycin resulted in an increase of p27 protein [20–23].
However, it is currently unknown which Akt isoform is involved in
the regulation of p27 protein.
The level of p27 may be regulated by transcription and/or
protein degradation which is mediated by the post-translational
modification-ubiquitination pathway [24–26]. Nuclear p27 may
bind to the Cdk2-cyclin D cell cycle engine to inactivate its kinase
activity, resulting in cell cycle arrest at G0/G1. The Akt-mediated
regulation of p27 could be through FoxO transcription factors
[27], mTOR [28], and/or direct phosphorylation of p27 at
Thr157 [29–31] and Thr198 [32]. Phosphorylated p27 by Akt is
translocated to the cytoplasm, where it is subjected to ubiquitin-
mediated proteasomal degradation by Skp2. This process is
required for cell cycle progression to occur (reviewed in [33]). p27
is also phosphorylated by Cdk2-cyclin E kinase at Thr187 during S
phase, which also becomes the target of Skp2-mediated protein
degradation (reviewed in [34]).
We found that p27 was localized to the nucleus of Akt2-ablated
cells, but a low level of p27 was ubiquitously present throughout
the entire cell in the control (Fig. 3A). (It should be noted that
transfection started and continued for 24 h prior to the 0 h
timepoint.) In addition, data from Western blotting showed that
Figure 1. Akt2 ablation resulted in a substantial decrease in cell proliferation and cell survival. (A) The isoform-specific siRNA oligos
used in this study effectively downregulated protein synthesis in an isoform-specific manner. Western blotting was carried out with samples isolated
from MDA-MB231 cells transfected with isoform-specific siRNA alone or in combination with other siRNA oligos as indicated. ‘‘R’’ denotes cells
transfected with reagent alone (i.e., a mock transfection control). Akt1–3 at the left of the panel denotes antibodies against Akt1–3 proteins,
respectively. c-tubulin was used as a loading control. Data shown is representative of four independent experiments using siRNA set #1. (B) Among
three Akt isoforms, Akt2 ablation caused the greatest decrease in the colony forming ability. Results shown have employed siRNA set #1. Data shown
is an average of three independent experiments. Error bars are standard errors. (C) Data from an MTT assay showed that ablation of Akt2
downregulated cell proliferation. MDA-MB231 cell proliferation was analyzed at 48–120 h post-transfection using siRNA set #2. Data shown is
representative of four independent experiments. (D) DNA replication is dramatically downregulated in MDA-MB231 cells transfected with Akt2 siRNA.
Cells were pulse-labelled with BrdU for 45 min, followed by analysis of DNA replication at 0–48 h post-transfection with an anti-BrdU antibody. Both
siRNA oligos to Akt2 (#1 and #2) show reduced cell proliferation relative to the control (p,0.05). Data is expressed as mean BrdU incorporation, and
error bars are standard errors. Results shown are an average of three independent trials.
doi:10.1371/journal.pone.0014614.g001
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transfected with Akt2 siRNA than the control (Fig. 3B, C).
Together, our data suggests that both the nuclear localization and
the elevated level of p27 play important roles in the G0/G1 cell
cycle arrest by Akt2 ablation.
If the nuclear localization of p27 was mediated through its
phosphorylation by Akt, the level of phosphorylated p27
(particularly on the Thr157 residue) would be lower in the Akt2-
ablated cells than in the scrambled control. Surprisingly, both Akt-
mediated phosphorylation sites (Thr157 and Thr 198) were not
significantly altered by the Akt2-ablation (Fig. 3B; Fig. S5A, B).
However, phosphorylation at Thr187 was upregulated in the
Akt2-ablated cells, compared to the control (Fig. 3B, D). This
could be due to the decrease in the Skp2-mediated degradation of
phosphorylated p27 at Thr187 in the Akt2-ablated cells, as the
level of Skp2 was markedly downregulated in Akt2-ablated cells
across all the timepoints examined (Fig. 3B).
Since the regulation of p27 in the Akt2-transfected cells was not
mediated by the Thr157 and Thr198 Akt-mediated phosphory-
lation, we examined the level of p27 mRNA by quantitative PCR.
As expected, cells maintained in serum-free medium for 24 h (i.e.,
the duration of the entire siRNA transfection) contained a high
level of p27 mRNA, regardless of the Akt2 status (Fig. S5C, 0 h).
Once cells were released into complete medium after the
transfection procedure ended, the level of p27 mRNA was lower
both in the control and Akt2-ablated cells by 24 h post-
transfection; however, the relative level was much lower in the
Akt2-ablated cells than the control (Fig. S5C). This result was
surprising since the p27 protein level was higher in Akt2-ablated
cells than the control at the same timepoint (Fig. 3B, lines 2 and 8;
Fig. 3C, 24 h). This data may suggest that p27 protein was more
stable upon release into complete medium, and this could
potentially be the result of the downregulation of Skp2 at the
same timepoint (Fig. 3B). The level of p27 mRNA in Akt2-ablated
cells became more abundant by 48 h, followed by a peak at 72 h
post-transfection (Fig. S5C, D). Collectively, the level of p27
mRNA generally follows that of p27 protein in the Akt2-ablated
cells, with the exception of the 24 h post-transfection timepoint.
Figure 2. Cdk2 and cyclin D were downregulated in cells transfected with Akt2-siRNA. (A) The relative level of Cdk2 was measured in a
time course manner (0–120 h post-transfection) after cells were transfected with Akt2 siRNA (set #2). (Lower panel) The relative intensity of bands
shown in the upper panel was normalized with the loading control and presented in a graph format. ‘‘No serum’’ denotes Opti-MEM transfection
medium described in Materials and Methods. ‘‘Full’’ denotes culture medium containing 10% FBS (i.e., complete medium). (B) Analysis of Cdk2 by
immunostaining in cells transfected with Akt2 siRNA (either oligo #1o r#2). The sampling times were 24 and 48 h post-transfection. Images shown
are representative of three independent trials for each timepoint and each siRNA, respectively. (C) Akt2 ablation resulted in the downregulation of
cyclin D, but not cyclin A and E. Western blot analysis of cyclin A, D and E of the cells transfected with Akt2 siRNA or scrambled siRNA was carried out
at 0–120 h post-transfection. Note that the 0 h timepoint is incubated for 24 h in serum-free medium for both Akt2-siRNA and scrambled-siRNA
treated cells. Data shown is representative of three independent experiments.
doi:10.1371/journal.pone.0014614.g002
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altered by the ablation of Akt1 or Akt3 (Fig. S6).
Akt2 ablation markedly downregulated the
phosphorylation of p70S6K at Thr389
Akt regulates cell proliferation and survival through the
activation and/or inactivation of many downstream substrates,
including GSK-3b [35] and Forkhead (FoxO) transcription factors
[36]. mTOR and TSC2 (tuberin, an upstream regulator of
mTOR) also regulates cell cycle progression through the
upregulation and stabilization of p27 [37–39], in addition to their
function in protein synthesis through p70S6K and 4E-BP1. We
determined whether these Akt downstream proteins are regulated
in an Akt2 isoform-specific manner. Data obtained from Western
blotting showed that neither the level of total protein nor
phosphorylation of FoxO1 at Ser256 was notably altered by
Akt2 ablation (Fig. S7A), suggesting that the upregulation of p27
transcription in Akt2-ablated cells is independent of the FoxO1
signaling pathway. Similarly, neither the level of GSK-3b protein
nor its phosphorylation status at Ser9 and Ser21 was substantially
altered in Akt2-ablated cells (Fig. S7B).
To ensure that the decrease in cell proliferation by Akt2
ablation was not due to the downregulation of the MAPK
pathway, protein levels of p-ERK1/2 (p42/44) were also
examined. We found that the phosphorylation pattern of
ERK1/2 (p42/44) was not substantially different between cells
transfected with Akt2 siRNA or scrambled siRNA (Fig. S7B).
Together, these data suggest that Akt2 is not involved in the
regulation of ERK, GSK-3b, or FoxO1 signaling pathways in the
MDA-MB231 cell line.
Since Akt is known to regulate cell cycle progression through the
mTOR signaling pathway, the activities of the two branches of the
mTOR pathway, p70S6K and 4E-BP1 (eukaryotic initiation
factor 4E-binding protein 1) were examined. As shown in Fig. 4A,
the phosphorylation of p70S6K at Thr389 was almost completely
downregulated in the cells transfected with Akt2 siRNA, although
Figure 3. p27 was localized to the nucleus and its level increased in Akt2-ablated cells. (A) Data from immunostaining assays shows that
p27 was mainly localized to the nucleus of the cells transfected with Akt2 siRNA. Confocal images shown are representative of three independent
experiments. (B) Akt2-ablated cells showed an increase in the level of p27 but a decrease in Skp2 proteins. The relative levels of total (C) and
phosphorylated p27 proteins at T187 (D) are shown.
doi:10.1371/journal.pone.0014614.g003
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ablation. Unlike p70S6K, however, neither the level of protein nor
the phosphorylation status of 4E-BP1 was substantially altered in
the Akt2-ablated cells (Fig. 4A). Collectively, these data demon-
strate that Akt2 is involved in the regulation of cell proliferation
and protein synthesis through the mTOR-p70S6K signaling
pathway in MDA-MB231 cells. In contrast to Akt2-ablated cells,
the phosphorylation status of p70S6K was not substantially altered
by either Akt1 or Akt3 ablation (Fig. S6).
AMP-activated protein kinase (AMPK), which is responsive to
cellular energy depletion, can inhibit cell growth through TSC2-
dependent suppression of mTOR signaling [40,41]. Data
presented by Hahn-Windgassen et al. [42] supports that Akt
functions upstream of AMPKa. It is also known that AMPKa
phosphorylates TSC2, thereby, constraining mTOR activity [43].
To determine whether the downregulation of the mTOR-p70S6K
pathway through Akt2 ablation was mediated by the activation of
AMPKa, we examined the relation between AMPKa and Akt2
ablation. Data in Fig. 4B shows that the levels of both AMPKa
protein and phosphorylation at Thr172 were moderately down-
regulated in Akt2-ablated cells maintained in complete medium. It
should be noted that AMPKa was activated (i.e., phosphorylated
at Thr172) by serum deprivation (i.e., during the 24 h transfection
period), regardless of the Akt2 status (Fig. 4B, lanes 1, 7).
Mitochondrial volume was increased in Akt2-ablated
cells
It was previously shown that Akt2 was physically associated with
the mitochondria in a variety of cancer cell lines including MDA-
MB231 [44]. Therefore, the mitochondrial status of the Akt2-
ablated cells was examined in conjunction with MitoTracker Red
CMXRos, a mitochondrial membrane potential-dependent dye
that is incorporated into actively respiring cells. The mitochondria
in MDA-MB231 cells normally present in one of the following two
morphologies: (i) aggregates around the perinuclear region; or (ii)
rounded punctuate structures in the cytoplasm (Fig. 5A, panels viii,
xi). However, the mitochondria in Akt2-ablated cells were spread
more widely in the cytoplasm, and the overall volume was
substantially increased (Fig. 5A, compared panels v and xi). A
computer-assisted analysis of the mitochondrial surface area
showed that the total area of the mitochondria in Akt2-ablated
cells was approximately 2-fold greater than that of the control
(p,0.001) (Fig. 5B). The total area of the entire cell surface was
not notably altered by Akt2 ablation (Fig. 5C), suggesting that the
increase in the mitochondrial surface area in Akt2-ablated cells
was not due to an increase in cell size (p.0.05, ns).
Peroxisome proliferator-activated receptor c coactivator-
1a (PGC-1a) was upregulated in Akt2-ablated cells
The increase in the mitochondrial volume in Akt2-ablated cells
could be due to an increase in mitochondrial biogenesis, which is
regulated by components of the AMPK, FoxO, and nitric oxide
pathways [45–47]. mTOR has also been demonstrated to directly
regulate mitochondrial biogenesis, or through the upstream
AMPK signaling pathway [48,49]. Alterations in any of these
pathways may result in the inhibition or activation of PGC-1a.
Thus, PGC-1a is the central player for mitochondrial biogenesis
and gluconeogenesis [50–52].
With respect to mitochondrial biogenesis, the following two
signaling mechanisms could be relevant to the phenotype shown in
the Akt2-knockdown cells. First, insulin suppresses FoxO1
transcription in an Akt-dependent mechanism, resulting in the
prevention of FoxO1 binding to PGC-1a, which in turn can
inhibit the transcription of genes involved in gluconeogenesis [53].
However, there was no notable alteration in FoxO1 phosphory-
lation at Ser256 in the Akt2 knockdowns (Fig. S6A). Second, Li
et al. [54] demonstrated that Akt2 phosphorylated PGC-1a at
Ser570 could inhibit the transcription of genes involved in
gluconeogenesis in a manner independent of FoxO1 in hepato-
cytes. Since an antibody specific for phosphorylated PGC-1a at
Figure 4. Ablation of Akt2 resulted in the downregulation of phosphorylated p70S6K and AMPKa. (A) Akt2 ablation caused the
downregulation of p70S6K phosphorylation at T389. The activation of the mTOR pathway was analyzed by Western blotting using extracts from
MDA-MB231 cells transfected with Akt2 siRNA or scrambled siRNA. The numbers 0–120 on the top of the panel are the sampling timepoints (h) after
transfection. (B) Akt2 ablation slightly downregulated AMPKa. Note that the highest levels of p-AMPKa occur in both the Akt2-ablated and scrambled
controls at the 0 h timepoint (i.e., during the serum starvation period) while the levels are lower in the Akt2-ablated cells in the later timepoints (48–
120 h; i.e., maintained in complete medium). Western blot shown for p-AMPKa was replicated four times, while AMPKa was replicated in triplicate.
doi:10.1371/journal.pone.0014614.g004
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PGC-1a proteins in Akt2-ablated cells as an alternative. As shown
in Fig. 6, the level of PGC-1a was elevated in the Akt2-ablated
cells at least up to 96 h post-transfection. This data suggests that
Akt2 ablation resulted in an increase of mitochondrial biogenesis
through the PGC-1a pathway. The level of PGC-1a decreased to
the same level of the scrambled control by 120 h post-transfection,
probably due to the start of mitochondrial autophagy (see Fig. 7
and relevant discussion below).
Akt2-ablated MDA-MB231cells eventually died by
mitochondrial autophagy
Cells may undergo autophagy when the mTOR pathway is
blocked; the upregulation of p27 persists; or the downregulation of
Cdk2 is prolonged [52,55]. All of these abnormalities were observed
in Akt2-ablated MDA-MB231 cells (Figs. 2–4), suggesting that
Akt2-ablated cells may undergo autophagy. To test this hypothesis,
we analyzed the level and migration of LC3B. LC3B-I is lipidated
(i.e., phosphatidylethanolamine conjugated) during the activation of
autophagy, which becomes associated with newly formed autopha-
gosomes [56,57]. Since the lipidated form (i.e., LC3B-II) migrates
slightlyfast onthegel,thiscanbeagood markerforthe activation of
autophagy. As expected, the level of LC3B-II was substantially
higher in Akt2-ablated cells than the control (Fig. 7A). This data is
consistent with the idea that Akt2 ablation induces autophagy. In
contrast, the levels of LC3B-II did not notably increase in cells
transfected with Akt1 siRNA or Akt3 siRNA, compared to cells
transfected with scrambled siRNA (Fig. S8).
Serum-starvation, rapamycin, and PI3K inhibitors (such as
wortmannin and LY294002) are all inducers of autophagy. It
should be noted that the level of LC3B-II is high in the cells
maintained in serum-free medium for 24 h during the transfection
period (Fig. 7, 0 h timepoint), suggesting that a substantial number
of cells undergo autophagy under the serum starvation conditions,
regardless of the Akt2 status. Thus, the 0 h timepoint can
essentially function as a positive control for the activation of
autophagy. The level of LC3B-II is also high at the 120 h
timepoint in the control. This may be due to nutrient depletion in
the growth medium since the cells at this timepoint were confluent
(Fig. 7A, scrambled control, 120 h).
Figure 5. (A) Akt2 ablation caused an increase in the mitochondrial volume. Cells transfected with either Akt2 siRNA (i–vi) or scrambled
siRNA (vii–xii) were immunostained with anti-Akt2 antibodies (Akt2) (green) or MitoTracker (red). Samples were taken at 0 or 48 h post-transfection as
indicated. It should be noted that Akt2 is co-localized with mitochondria (ix, xii) as described previously [102]. Cells at 0 h were in the Opti-MEM
(serum-free) for 24 h during transfection, and those at 48 h were maintained in the complete medium containing 10% FBS for 48 h after the
transfection procedure was complete. Note that the 20 mm size bar of the scrambled samples is 1.3 fold bigger than that of Akt2-treated samples. (B)
The relative surface area of the total mitochondria was compared to the total surface area of the cell (mm
2). The quantification of the cells surface area
was carried out using software installed in the LSM 510 Meta laser scanning confocal microscope (Carl Zeiss). For the quantification, at least ten fields
were analyzed for each sample. Error bars are standard errors. (C) The same as panel (B), except this data shows total cell area (mm
2).
doi:10.1371/journal.pone.0014614.g005
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examined the presence of autophagosomes using an immuno-
staining method with an anti-LC3B antibody, MitoTracker Red
CMXRos, and DRAQ5 (nuclear staining). Data shown in Fig. 7B
suggested that autophagosomes were co-localized with the
mitochondria in cells transfected with Akt2 siRNA (Fig. 7B, iv),
but not in the control (Fig. 7B, viii). In contrast, Akt1- or Akt3-
ablated cells showed only the background level of autophagosomes
(Fig. S8, iv, viii, and xii).
We further examined the induction of autophagy in Akt2-
ablated cells using monodansylcadaverine (MDC), an autofluor-
escent compound shown to be incorporated into autophagolyso-
somes [58,59]. In this experiment, cells were concurrently stained
with acridine orange (AO) to observe the overall cell morphology
and acidic vesicular organelles [60], and MitoTracker Red
CMXRos to label mitochondria. Data from this experiment
showed that the mitochondria were visibly enlarged and co-
localized with MDC by 96 h post-transfection with Akt2 siRNA
(Fig. 7C, compared panels ii–iv with x–xii). By 120 h post-
transfection, the mitochondria in the Akt2-ablated cells were
largely collapsed (Fig. 7C, compared panels vi–viii with xiv–xvi).
Together, our data obtained from three different approaches
suggest that the mitochondria are selectively targeted for
autophagic degradation when the ablation ofAkt2 persists in
MDA-MB231.
Discussion
Although Akt has been known to play an important role in cell
proliferation and survival, the functional mechanism contributed
by each isoform on these pathways is poorly understood. Using
isoform-specific siRNA and the MDA-MB231 cell line as a breast
cancer cell model, we examined the unique role of each Akt
isoform on cell proliferation and survival. Our data demonstrates
that Akt2 is the most critical player in the regulation of cell
proliferation and survival among the three isoforms, at least in the
breast cancer model examined (Fig. 1). Ablation of Akt2 promoted
cell cycle arrest at G0/G1 through the downregulation of Cdk2
and cyclin D, and upregulation of p27, resulting in a decrease of
cell proliferation. In addition, Akt2 ablation profoundly affected
the mitochondria, initially increasing its volume and, eventually,
causing cell death by mitophagy. As illustrated in Fig. 8, we found
that Akt2 is not involved in the regulation of some of the known
pan-Akt downstream substrates such as FoxO1, GSK-3a/b, and
ERK1/2 in MDA-MB231 cells. The data presented in this paper
lends further support to the growing lines of evidence in the
literature that each Akt isoform regulates specific pathways.
The role of Akt2 in the regulation of cell cycle
progression and cell proliferation
While the rate of proliferation decreased in the cells transfected
with Akt1- and Akt3-siRNA, cells void of Akt2 consistently showed
the most pronounced decrease in proliferation among the three
isoforms (Fig. 1C and Fig. S1C, D). This is, in part, due to the
unique role of Akt2 in the promotion of cell cycle progression, as
the ablation of Akt2 caused decreases in the levels of Cdk2 and
cyclin D (Figs. 1–3). Cdk2 forms a complex with cyclin A or E,
while cyclin D forms a complex with Cdk4 or Cdk6 [61].
Therefore, the downregulation of only two proteins (i.e., Cdk2 and
cyclin D) in Akt2-ablated cells can ensure the effective arrest of the
cell cycle in G0/G1 by simultaneously inactivating the Cdk2, 4
and 6 cell cycle engines.
The ablation of Akt1 did not notably alter the level of p27 (Fig.
S6A), although it resulted in the downregulation of cyclin D (Fig.
S4A). This data suggests that Akt1 also promotes cell cycle
progression, but less effectively than Akt2 in MDA-MB231 cells.
In contrast to Akt1 and Akt2, the ablation of Akt3 did not alter the
level of Cdk2 (Fig. S3A), cyclin D (Fig. S4B), or p27 (Fig. S6B),
suggesting that Akt3 is not directly involved in the regulation of
cell cycle progression or proliferation in MDA-MB231 cells.
The upregulation of p27 in Akt2-ablated cells is another
mechanism of effectively arresting cells in G0/G1 through the
inactivation of Cdks [62]. We found that the upregulation of p27
in Akt2-ablated cells was mainly due to an increase in mRNA
levels (Fig. S5C). However, p27 upregulation during the first 24 h
after Akt2 ablation (i.e., 24 h post-transfection) may be due to the
increase in protein stability (i.e., the 24 h timepoint in Fig. S5C;
Fig. 3B, C). Since Skp2 was severely downregulated in Akt2-
ablated cells at the same timepoint, this may have resulted in the
Figure 6. Akt2-ablation resulted in an increase of the PGC-1a protein level. (A) The level of PGC-1a was analyzed by Western blotting in
MDA-MB231 cells transfected with Akt2 siRNA or scrambled siRNA. Data shown is representative of three independent trials. (B) The level of PGC-1a
obtained by scanned gel images (in panel A) was analyzed by densitometry (Alpha Innotech). The intensity was normalized with that of c-tubulin.
doi:10.1371/journal.pone.0014614.g006
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with published data that the level of p27 protein is regulated by
both transcription and protein stability [63–65]. It should also be
noted that p27 was mainly localized in the nucleus of Akt2-ablated
cells, which can effectively downregulate Cdks (Fig. 3A). Along
with the downregulation of Cdk2, cyclin D, and Skp2, the
upregulation of p27 essentially guarantees the complete arrest of
the cell cycle at G0/G1 in the Akt2-ablated cells.
Data presented here are largely consistent with numerous
previous publications with respect to the role of Akt in facilitating
cell cycle progression, cell proliferation, and the downregulation of
p27, although many of them did not examine Akt in an isoform-
specific manner [66–77]. However, our data is not consistent with
that of Yang et al. [78]. Data obtained from experiments using
constitutively active myristoylated Akt constructs, these authors
concluded that both Akt1 and 2 efficiently inhibited the growth
and proliferation of MDA-MB231 cells. The authors also
concluded that Akt2 increased the stability and nuclear localiza-
tion of p27, thus inhibiting cell cycle progression. Since these
conclusions are completely opposite of what we describe in this
paper, an important question arises: why are the conclusions by
Yang et al. [79] and our group (and numerous other laboratories)
completely different? We note that the experimental approach
taken by Yang et al. [80] was very different from that of ours: they
introduced constitutively active myristoylated Akt into the MDA-
MB231 using an adenovirus-based vector, while our study used an
siRNA-based approach under physiological conditions. It should
be noted that cells may activate a negative feedback and/or cross-
inhibitory control mechanism(s) under an extremely high level of
constitutively active Akt [81–83]. Indeed, some of the data shown
by Yang et al. [84] appear to support the activation of these
negative control mechanisms, which might have resulted in
Figure 7. Akt2 ablation induced autophagy of mitochondria. (A) Akt2 ablation with siRNA resulted in an increase of LC3B-II. Western blotting
was carried out with anti-LC3B antibody that recognizes both LC3B-I and LC3B-II. Cell extracts from Akt2-ablated or control cells (scrambled) were
prepared at the timepoints indicated. ‘‘No’’ denotes no serum in the medium (i.e., Opti-MEM). Note the increased LC3B-II levels in the Akt2-ablated
cells compared to the scrambled controls. (B) Immunofluorescent staining of LC3B was carried out at 96 h post-transfection. Red, green, and blue are
MitoTracker (mitochondrial detection), LC3B (detection of LC3B, which is associated with autophagosomes), and DRAQ5 (nucleus detection),
respectively. Akt2 siRNA and ‘‘Scrambled’’ denote MDA-MB231 cells transfected with Akt2 siRNA or scrambled siRNA, respectively. (C) Cells on a glass
coverslip were transfected with Akt2 siRNA or scrambled siRNA, followed by triple-staining, first with MitoTracker Red, followed by acridine orange
(AO) and monodansylcadaverine (MDC). Sampling timepoints after transfection are indicated left to panel.
doi:10.1371/journal.pone.0014614.g007
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it is also important to note that Akt2 is localized at the
mitochondria under physiological conditions [85]. It is presently
unknown whether the Akt2-specific signaling is activated at the
inner leaflet of the plasma membrane, similarly to the activation of
Akt1. However, Yang et al. [86] assumed in their experiments that
Akt2 is activated at the inner leaflet of the plasma membrane,
which may or may not be correct. The constitutive activation of an
extremely high level of myristoylated Akt2 at the plasma
membrane is likely to alter the normal Akt and, possibly, other
signaling pathways in the cell.
Akt2 regulates p70S6K
The phosphorylation of p70S6K at Thr389 was almost
completely downregulated in the Akt2-ablated MDA-MB231
cells, but not in the Akt1- or Akt3-ablated cells (Fig. 4A; Fig.
S6). The finding that Akt2 signaling passes exclusively through the
mTOR-p70S6K pathway was somewhat surprising, since pub-
lished reports often speculated that the downstream signaling
substrates of all three Akt isoforms were redundant. Clearly, our
data does not support this previous suggestion. Consistent with our
findings, Veilleux et al. [87] recently reported that the inhibition of
mTORC1/S6K1 had little effect on Akt1 activation, but resulted
in a significant decrease of Akt2 activity in 3T3-L1 adipocytes
[88]. Moreover, the authors did not observe any alterations in p-
AMPK when the function of mTORC1 was inhibited. Among
many functions ascribed to the mTOR pathway, one of the most
important functions is the regulation of protein synthesis. Akt2 is
also known to regulate glucose transport and gluconeogenesis, and
the inhibition of Akt2 function was associated with defects in
glucose uptake [89]. Thus, our data is consistent with the idea that
the Akt2-mTOR-p70S6K pathway is critical for cellular energy
and metabolism that are directly relevant to cell proliferation and
survival.
Protection of mitochondrial autophagy by Akt2
One of the most exciting findings in the present study is the
observation that the ablation of Akt2 had severe effects on the
mitochondria of MDA-MB231 cells. The co-localization of Akt2
and the mitochondria from our previous study [90] provided the
rationale to examine the mitochondria in the Akt2-ablated cells.
The mitochondrial size and surface area increased substantially in
the Akt2-ablated cells, suggesting that these cells had increased
their mitochondrial content (Fig. 5). This finding was surprising
since Akt2 ablation downregulated the protein synthesis pathway
(Fig. 4). It was recently shown that signaling to PGC-1a may be
Figure 8. Summary of the Akt2-specific signal pathway and a proposed model. Akt2 facilitates cell cycle progression by regulating two
separate pathways: (i) upregulation of Cdk2 and Cyclin D, and (ii) downregulation of p27 at the levels of transcription and protein stability through
the upregulation of Skp2. In addition, Akt2 prevents abnormal mitochondrial biogenesis and pathological autophagy through the activation of
p70S6K (i.e., phosphorylation at Thr389) and downregulation of PCG-1a. Broken lines and arrows are considered to be part of the pan-Akt pathway;
however, our data suggests that Akt2 is not involved in the regulation of these signaling pathways. ‘‘6’’ denotes that these signaling pathways are
not affected by Akt2 ablation. Solid lines are signaling pathways that have been confirmed by data presented in this paper. Arrows and ‘‘ I —’’ denote
up- and downregulation, respectively. ¤ denotes that this signal could cause abnormal mitochondrial biogenesis in the absence of Akt2.
doi:10.1371/journal.pone.0014614.g008
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[91]. These authors demonstrated that phosphorylation of PGC-
1a at Ser570 by Akt2 in hepatocytes inhibited the activation of
PGC-1a and prevented the transcription of genes involved in
gluconeogenesis [92]. Consistent with this previous finding, our
data showed that the downregulation of Akt2 resulted in an
increase of PGC-1a. Thus, this data validates the report of Li et al.
[93], and further extends their findings by demonstrating that the
deregulation is due to prolonged Akt2 inhibition.
One of the most critical consequences of Akt2 ablation is that it
eventually leads a cell to pathological autophagy (Fig. 7). Most
interestingly, the unique feature of this autophagy is that the
mitochondria are the specific target (Fig. 7). However, this finding
may not be unexpected since we have recently found that Akt2 is
associated with the mitochondria [94]. An important conclusion
derived from our study is that Akt2 wild type may be a critical
protector of the mitochondria.
One interesting question is, how may an initial increase in the
mitochondrial volume eventually lead to mitophagy? Our data
suggests that Akt2 is involved in the regulation of mitochondrial
biogenesis, as it apparently modulates PGC-1a (Fig. 6). Since the
mTOR-p70S6Kpathwayismarkedlydownregulated(Fig.4A),new
protein synthesis is limited in Akt2-ablated cells. Under these
conditions, the usage of proteins would have to be closely
monitored. Uncontrolled mitochondrial biogenesis caused by the
inactivation of the Akt2-mediated ‘‘surveillance’’ mechanism would
result in an abnormal increase of the mitochondrial volume. This
hypothesis is supported by the fact that PGC-1a was upregulated in
Akt2-ablated cells (Fig. 6). Since uncontrolled ‘‘growth’’ of the
mitochondria occurs while protein synthesis is severely limited due
tothedownregulation ofp70S6K,thehigh activityofmitochondrial
biogenesis cannot be sustainable for an extended duration in the
Akt2-ablated cells. Thus, the deregulation of mitochondrial
biogenesis in Akt2-ablated cells may eventually lead to the collapse
of the entire mitochondrial homeostasis system (and may start to
salvage the mitochondria to increase survivability). Hickson-Bick et
al. [95] observed a similar phenomenon when PGC-1 was
stimulated with lipopolysaccarides. We found that the ablation of
neither Akt1 nor Akt3 resulted in mitophagy (Fig. S8). This may be
relevant to the fact that, unlike Akt2 which is associated with the
mitochondria, Akt1 and 3 are localized mainly to the cytoplasm and
the nucleus, respectively [96].
In summary, among the three Akt isoforms, Akt2 is most
relevant for cell proliferation and survival in MDA-MB231 cells.
The former is achieved by the upregulation of Cdk2, cyclin D, and
Skp2 as well as the downregulation of p27, while the latter is
achieved by the activation of p70S6K and the modulation of
PGC-1a. Since the downregulation of p27 is also relevant to cell
survival [52], p27 is a key control point in the Akt2-mediated cell
regulation. In terms of cancer therapy, selective inhibitors for the
Akt isoforms have been developed but have not yet reached
clinical trials (reviewed in [97]). Clinical trials with rapamycin
have been shown to be effective in some, but not all cancers.
Further, Arboleda et al. [98] found that Akt2 overexpression
induced invasion and metastasis in breast and ovarian tumors.
Thus, the data presented in this paper provide grounds that Akt2
can be one of the most promising targets for anti-cancer therapies,
at least for breast cancer.
Materials and Methods
Cell Culture
The MDA-MB231 breast cancer cell line, purchased from
ATCC (Manassas, VA), was grown in RPMI-1640 medium
containing 10% (v/v) fetal bovine serum (Hyclone), 2.05 mM L-
glutamine, 100 mg/ml streptomycin and 100 units/ml penicillin.
Cells were maintained at 37uC in a humidified atmosphere with
5% CO2 and 95% air.
Antibodies, Chemicals, and Reagents
Antibodies against the following proteins were purchased from
Cell Signaling Technology (Danvers, MA): Akt1 (2H10), p-
FoxO1(S256), FoxO1, p-GSK-3a/b (S9/S21), GSK-3b,p -
p70S6K (T389), p70S6K, p-4E-BP1, 4E-BP1, p-AMPKa (T172),
AMPKa, and Skp2. Antibodies against the following proteins were
from Santa Cruz Biotechnology (SantaCruz, CA): Akt2 (F7),Cyclin
A, Cyclin D1, Cyclin E, p-ERK1/2 (p42/p44), p-p27 (T187), p27,
and PGC-1a. Anti-phospho-p27 Thr157 and -Thr198 antibodies
were from R&D Systems (Minneapolis, MN). Anti-Cdk2 and -Akt3
antibodies were purchased from Lab Vision Corporation (Fremont,
CA) and Upstate Biotechnology (Lake Placid, NY), respectively.
Anti-mouse, -rabbit, and -goat peroxidase-conjugated secondary
antibodies were obtained from Sigma, Pierce, and Calbiochem,
respectively. Fluorescein (FITC)-conjugated AffiniPure donkey and
anti-mouse IgG secondary antibody used in the immunofluores-
cence experiments were from Jackson Immunoresearch (West
Grove, PA). Anti-c-tubulin antibodies, propidium iodide (PI),
thiazolyl blue tetrazolium bromide (MTT), dimethyl sulfoxide
(DMSO), acridine orange, and monodansylcadaverine (MDC) were
purchased from Sigma. Lipofectamine 2000 transfection reagent,
Opti-MEM I transfection media, DNAse I, and M-MLV were from
Invitrogen. MitoTracker Red CMXRos Mitochondrial Probe was
from Cambrex Bioscience Walkersville, Inc. (Charles City, Iowa).
Methylene blue was from Acros Organics (Fisher).
Small interfering RNA (siRNA)
Cells (,30% confluence) were plated 24 h prior to transfection
with siRNA in antibiotic-free medium. Transfections were carried
out using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. Transfection was carried out in Opti-
MEM Reduced Serum Medium (Invitrogen) for 24 h. The 0 h
timepoint described throughout this manuscript is defined as the
end of the transfection procedure (i.e., 24 h after transfection was
initiated). The ‘‘Reduced Serum Medium’’ does not actually
contain any FBS (hence, denoted as ‘‘no serum’’ in this paper). At
the 0 h timepoint, the medium was replaced with RPMI 1640
supplemented with 10% FBS (Hyclone) in all subsequent
timepoints (24–120 h), which is defined as complete medium.
To knockdown each Akt isoform, two different siRNA oligonu-
cleotides for each Akt isoform were used: (A) siRNA set 1: Akt1 (59
GGCUCCCCUCAACAACUUC 39), Akt2 (59 GGAUGAA-
GUCGCUCACACA 39), and Akt3 (59 GGACCGCACAC-
GUUUCUAU 39). (B) siRNA set 2: Akt1 (59 GCCCUCAGAA-
CAAUCCGAU 39), Akt2 (59GGUCGACACAAGGUACUUC
39), and Akt3 (59 GGCCAAGAUACUUCCUUUU 39).
Control samples were transfected with scrambled siRNA
(Scrambled Control, 10 nM) or transfected with reagent alone
(Reagent Control). All siRNA oligonucleotides, including scram-
bled controls, were purchased from Ambion.
Cell proliferation and survival assays
Cell proliferation was measured using an MTT assay and BrdU
incorporation. For the MTT assay, cells were transfected with
siRNA specific to each Akt isoform in 10 cm plates (Sarstedt). At
the 24 h timepoint after transfection was initiated (i.e., 0 h
timepoint), cells were trypsinized, washed, and counted. Three
thousand cells (in 100 ml culture medium) were plated in a well of a
96-well clustered dish, and maintained until samples were taken at
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the leftover cells at 24 h (i.e., 0 h timepoint described in this paper)
was used for Western blot analysis to confirm the efficiency of the
siRNA transfection. At each timepoint, 10 ml of MTT stock
(5 mg/ml MTT in PBS) was added to each well and incubated for
4 h at 37uC, 5% CO2. The MTT-culture medium was gently
removed from the well using a pipette. 200 ml of DMSO was
added to each well and mixed thoroughly, followed by analysis
using a SPECTRAmax 340 PC plate reader (Molecular Devices).
Absorbance was measured at 570 nm (and 650 nm as reference
wavelength). All absorbance measurements were corrected to the
reference wavelength (Corrected absorbance=570–650 nm).
5-Bromo-29-deoxy-uridine (BrdU) incorporation was carried
out according to the manufacturer’s protocol (Roche). Briefly,
MDA-MB231 cells were plated on a 1.8-cm (0.13–0.17-mm thick)
sterile glass-coverslip (Fisher) that had been placed in the 6-well
plate 24 h prior to transfection. Cells on the coverslip were
transfected with siRNA, followed by analysis of BrdU incorpora-
tion at 0, 24, and 48 h post-transfection. BrdU pulse-labelling was
carried out during the last 45 min of each sampling timepoint. A
minimum of 10 fields per coverslip were documented using an
LSM 510 Meta laser scanning confocal microscope (Carl Zeiss)
with a 488-nm laser (filter settings 505–530 nm).
For the colony forming assay, cells harvested at 24 h post-
siRNA transfection were plated on a 10-cm dish (,1000 cells).
After 10–12 days of incubation, the culture medium was removed,
and the plates were gently washed with PBS. Cells were then fixed
and stained with 2% (w/v) methylene blue in 100% methanol for
10 min at room temperature. Colonies comprised of .50 cells
were counted as positives.
Immunostaining
Cells were plated on a 1.8-cm sterile glass coverslip that had been
placedina well ofa 6-wellclustereddish.Cellsonthecoverslipwere
transfected after overnight incubation. At a scheduled timepoint,
cells were washed with PBS, fixed with 4% paraformaldehyde for
10 min, and then permeabilized in 0.2% Triton X-100 for 5 min.
The coverslips were treated with blocking solution (10% horse
serum, 1% BSA, 0.02% NaN3, in PBS) for 1 h at room
temperature, followed by immunostaining with an appropriate
antibody. Primary antibodies (diluted in 1% BSA in TBS) were
incubated for 45 min at the following concentrations: Akt2 (1:10),
Cdk2 (1:20), and p27 (1:10), and then washed in TBS. A fluorescein
(FITC)-conjugated donkey anti-mouse IgG secondary antibody was
diluted 1:100 (1% BSA in TBS), and incubated for 30 min. The
coverslip was washed again in TBS, and mounted in 90% glycerol/
PBS. For double-labelling of Akt2 and MitoTracker, cells were first
incubated with 50 nM MitoTracker Red CMXRos in cell culture
media for 30–45 min (37uC, 5% CO2), followed by fixation and
permeabilization prior to immunostaining with an anti-Akt2
antibody. Immunostained cells were then observed by confocal
microscopy (LSM 510 Meta laser scanning microscope, Carl Zeiss)
using a 636objective lens and two laser lines for excitation with the
following band pass settings: Argon 488 nm (band pass 505–
530 nm), HeNe 543 nm (long pass 560 nm). Images were captured
using an LSM 510 Meta confocal microscope and associated
software. Mitochondrial surface and total cell areas were calculated
using the same software. The relative mitochondrial surface area
was calculated as follows: [(mitochondrial surface area/total cell
surface area of a cell)] (in mm
2).
Quantitative PCR (Q-PCR)
Total RNA was extracted from cells using an RNeasy kit
(Qiagen) according to the manufacturer’s protocol. The concen-
tration of RNA was measured using a spectrophotometer (UV
1101 Biotech Photometer) and the integrity was verified by
agarose gel (1%) electrophoresis. One microgram of DNAse I-
treated RNA was reverse transcribed with M-MLV (Invitrogen)
and 10 mM dNTPs (IB Labs). Q-PCR was carried out as
described previously [99] using an ABI Prism 7900 HT Sequence
Detection System (SDS) (Applied Biosystems). The PCR condi-
tions were as follows: 95uC for 15 s, 55uC for 15 s, and 72uC3 0s ,
for 40 cycles. The RNA isolated from the control was used to
calibrate the standard curve. The mRNA levels were calculated by
comparing the ratio of Akt2:S28 and p27:S28. The following
primers were used for PCR reactions (300 nM): Akt2 forward 59-
CAAGGATGAAGTCGCTCACACA-39 and Akt2 reverse 59-
GAACGGGTGCCTGGTGTTC-39; p27 forward 59-CGGT-
GGACCACGAAGAGTTAA-39 and p27 reverse 59-GGCTC-
GCCTCTTCCATGTC-39. Primer sequences for the S28 house-
keeping gene were as follows: S28 forward 59-TCCATCATCCG-
CAATGTAAAAG-39 and S28 reverse 59-GCTTCTCGC-
TCTGACTCCAAA-39. Data was acquired and analyzed using
ABI SDS software (version 2.1) (Applied Biosystems).
Detection of autophagy
Cells (transfected with siRNA) were incubated with 50 nM
MitoTracker Red CMXRos in culture media for 30 min in a cell
culture incubator, followed by treatment with acridine orange
(1.0 mg/ml) and MDC (a specific marker for the autophagosome)
(0.05 mM) as described previously [58,60,100,101]. Cells were
then rinsed with PBS and mounted on a glass slide for visualization
by fluorescent microscopy. Fluorescent images were captured with
an LSM 510 Meta confocal microscope (Carl Zeiss) using a 636
objective and three laser lines for excitation with the following
band pass filter settings used for detection: Argon 488 (band pass
505–530 nm), HeNe 543 nm (long pass 560) and 633 nm (long
pass 650).
To determine the process of autophagy, the induction of LC3B
was examined in cells transfected with Akt2 or scrambled siRNA.
At 96 h post transfection, cells were washed in PBS, fixed in 4%
paraformaldehyde, and permeabilized with 100% (v/v) ice-cold
methanol for 10 min at 220uC. The cells on coverslips were then
treated with blocking solution for 1 h at room temperature. The
primary antibody (LC3B) was diluted in TBS containing 1% BSA
prior to adding to the cells, which was incubated overnight at 4uC.
The next day, the cells were washed and incubated with secondary
antibody. Finally, cells were rinsed and counterstained with
DRAQ5 (10 mm) for 30 min at room temperature (Biostatus
Ltd., Shepshed, Leicestershire, UK), prior to visualization by
confocal microscopy.
Statistical analysis
A univariate 2-way ANOVA with subsequent post-hoc analysis
for significance testing (Tukey p,0.05) was used to determine
differences in cellular proliferation and BrdU incorporation, as
well as in the analyses of mitochondrial surface area. Univariate
analysis of variance (One-way ANOVA) was carried out to analyze
colony formation ability. All statistics were performed using SPSS
v.12.0 for Windows.
Supporting Information
Figure S1 Akt2 ablation resulted in a decrease of cell
proliferation and survival. (A). Western blotting was carried out
with samples isolated from MDA-MB231 cells transfected with
isoform-specific siRNA Set #2 alone or in combination with other
siRNA oligos as indicated. ‘‘R’’ denotes cells transfected with
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of the panel denotes antibodies against Akt1–3 proteins,
respectively. c-tubulin was used as a loading control. Data shown
is representative of four independent experiments. (B) Colony-
forming assay with siRNA Set #2. As with the Set #1 sample,
siRNA targeted to Akt2 caused the greatest decrease in colony
forming ability. Results shown are an average of four independent
trials. Data are expressed as the average mean colony formation,
and error bars are standard error.
Found at: doi:10.1371/journal.pone.0014614.s001 (0.79 MB
TIF)
Figure S2 Cells transfected with Akt2 siRNA were arrested at
G0/G1 phase. MDA-MB231 cells were transfected with Akt2
siRNA, and their cell cycle positions were determined by flow
cytometry. 0 h, 24 h and 48 h on top of the panels are time (h) post-
transfection (for 24 h in Opti-MEM which does not contain FBS).
‘‘Reagent’’ and ‘‘Controls’’ are mock transfection and ‘‘kept-in-
incubator’’ controls, respectively. 2n and 4n are two (i.e., G1 phase)
and four (G2/M phase) chromosomal contents, respectively.
Found at: doi:10.1371/journal.pone.0014614.s002 (0.54 MB
TIF)
Figure S3 Cdk2 is downregulated in Akt2-, but not Akt1- and
Akt3-ablated cells. (A) Western blot assays with anti-Cdk2 or -c-
tubulin (loading control) antibodies were carried out with MDA-
MB231 cells transfected with siRNA specific to Akt1, 2, 3, or in
combination. The sampling time was 24 h post-transfection. ‘‘R’’
is as per legend to Figure 1. ‘‘C’’ denotes a control kept in the
incubator during the transfection process. (Lower panel) The
relative level of Cdk shown in the upper panel was quantified by
densitometry and normalized with loading control. (B) The
relative level of Cdk2 measured in a timecourse manner (0–
120 h post-transfection) in cells transfected with a second set of
Akt2 siRNA oligo (Set #1). Data was generated by densitometry
from Western blot. Data shown is from three independent
experiments. The relative levels of cyclin D1 (C) and cyclin E
(D) quantified with densitometry and normalized to the loading
control. Error bars are standard errors.
Found at: doi:10.1371/journal.pone.0014614.s003 (0.70 MB
TIF)
Figure S4 Effects of Akt 1 or Akt3 ablation on the level of cyclin
D. (A) Akt1 ablation in MDA-MB231 cells resulted in the
downregulation of cyclin D. (B) Ablation of Akt3 in MDA-MB231
cells resulted in little change in the level of cyclin D.
Found at: doi:10.1371/journal.pone.0014614.s004 (1.09 MB
TIF)
Figure S5 Levels of p27 phosphorylation at Thr157 (A) and
Thr198 (B) are shown. Shown is the Q-PCR-based analysis of p27
mRNA level (C) and Akt2 mRNA level (D). Data are results of
three independent experiments (in triplicate for each experiment),
and were normalized to the value of tubulin (for protein) or S28
mRNA (for mRNA). Error bars are standard errors.
Found at: doi:10.1371/journal.pone.0014614.s005 (0.59 MB
TIF)
Figure S6 The effects of Akt 1 and 3 on p27 and p70S6K. (A)
Akt1 ablation in MDA-MB231 cells did not affect the levels of p27
protein and p70S6K phosphorylation. (B) Ablation of Akt3 in
MDA-MB231 cells resulted in little changes in the level of
phosphorylation of p70S6K.
Found at: doi:10.1371/journal.pone.0014614.s006 (1.30 MB
TIF)
Figure S7 Examination of the downstream Akt pathways in
MDA-MB231 cells transfected with Akt2 siRNA or scrambled
siRNA. (A, B) Western blot analyses were carried out with
antibodies against proteins listed left to panels. c-tubulin was used
as loading control. Data shown are representative of three
independent experiments (p-ERK was performed in duplicate).
No serum, Opti-MEM transfection medium only; Full, complete
medium containing 10% FBS.
Found at: doi:10.1371/journal.pone.0014614.s007 (1.24 MB
TIF)
Figure S8 Neither the ablation of Akt1 nor Akt3 induced
substantial mitophagy. (A) Knockdown of Akt1 (left panel) and
Akt3 (right panel) with siRNA did not increase substantially the
amountofLC3B-II. Western blotting wascarried out withanti-LC3B
antibody that recognizes both LC3B-I and LC3B-II. The extracts
from Akt2-ablated or control cells (scrambled) were prepared at
timepoints indicated. ‘‘No’’ denotes no serum in the medium (i.e.,
Opti-MEM). (B) Cells were transfected with Akt1 siRNA (i–iv), Akt3
siRNA (v–viii), or scrambled siRNA (ix–xii), followed by immuno-
fluorescent staining. Red, green, and blue are MitoTracker
(mitochondrial detection), LC3B (mostly associated with autophago-
somes), and DRAQ5 (nucleus detection), respectively.
Found at: doi:10.1371/journal.pone.0014614.s008 (2.69 MB
TIF)
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